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Abstract
Prior real-world studies have shown that apixaban is associated with a reduced risk of
stroke/systemic embolism (stroke/SE) and major bleeding versus warfarin. However, few
studies evaluated the effectiveness and safety of apixaban according to its dosage, and
most studies contained limited numbers of patients prescribed 2.5 mg twice-daily (BID) apix-
aban. Using pooled data from 4 American claims database sources, baseline characteristics
and outcomes for patients prescribed 5 mg BID and 2.5 mg BID apixaban versus warfarin
were compared. After 1:1 propensity-score matching, 31,827 5 mg BID apixaban-matched
warfarin patients and 6600 2.5 mg BID apixaban-matched warfarin patients were identified.
Patients prescribed 2.5 mg BID apixaban were older, had clinically more severe comorbidi-
ties, and were more likely to have a history of stroke and bleeding compared with 5 mg BID
apixaban patients. Compared with warfarin, 5 mg BID apixaban was associated with a lower
risk of stroke/SE (hazard ratio [HR]: 0.70, 95% confidence interval [CI]: 0.60–0.81) and
major bleeding (HR: 0.59, 95% CI: 0.53–0.66). Compared with warfarin, 2.5 mg BID apixa-
ban was also associated with a lower risk of stroke/SE (HR: 0.63, 95% CI: 0.49–0.81) and
major bleeding (HR: 0.59, 95% CI: 0.49–0.71). In this real-world study, both apixaban doses
were assessed in 2 patient groups differing in age and clinical characteristics. Each apixa-
ban dose was associated with a lower risk of stroke/SE and major bleeding compared with
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Introduction
Vitamin K antagonists such as warfarin have been used as the anticoagulant therapeutic
modality for stroke prevention in patients with atrial fibrillation for several decades [1]. More
recently, non-vitamin K antagonist oral anticoagulants (NOACs) are being used at greater fre-
quencies and have several advantages to vitamin K antagonists, such as fewer drug–food inter-
actions and no anticoagulation monitoring being required [2]. In phase 3 clinical trials,
NOACs have demonstrated at least equivalent efficacy and safety compared to warfarin [3–6].
Apixaban was the only NOAC to show risk reductions in both stroke/systemic embolism
(stroke/SE) and major bleeding compared with warfarin in its phase 3 clinical trial [5].
Apixaban is available as: 5 mg twice daily (BID) and 2.5 mg BID. The recommended dose is
2.5 mg BID apixaban if patients meet2 of the following criteria: aged80 years, body weight
60kg, and serum creatinine level1.5mg/dL [7]. In the Apixaban for Reduction in Stroke
and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial, 4.7% of patients
in the apixaban group (n = 428) received 2.5 mg BID apixaban, and no significant interaction
was observed between dose and treatment effect regarding stroke/SE and major bleeding [5].
A subanalysis of ARISTOTLE trial data by Alexander et al. suggested that the use of apixaban 5
mg BID is appropriate for patients meeting only one of these dose reduction criteria [8].
Although previous real-world studies have shown that apixaban is associated with a reduced
risk of stroke/SE and major bleeding versus warfarin, most of these studies contained only lim-
ited numbers of patients taking 2.5 mg BID. In addition, few studies have evaluated the effec-
tiveness and safety of apixaban according to dosage, or have taken into consideration patient
characteristics related to dose reduction criteria [9–13]. Certain patient characteristics—
including older age and renal disease—are associated with an increased risk of stroke and
major bleeding, and dose-reduction criteria for apixaban are based on a patient’s age, body
weight, and renal function [14]. Because the characteristics of patients with nonvalvular atrial
fibrillation using 5 mg BID apixaban and 2.5 BID apixaban may differ [11, 15], clinicians
should evaluate clinical outcomes according to apixaban dosage while carefully accounting for
these key patient characteristics. Prior studies by Li et al. [16] and Yao et al. [12] included suba-
nalyses using interaction terms to test if the treatment effect on stroke/SE and major bleeding
varied between the 2 label-recommended apixaban dose regimens when compared to warfarin
using data from United States (US) clinical practice. While Yao et al. found a significant inter-
action between initial apixaban dose and the treatment effect of apixaban versus warfarin on
major bleeding (p = 0.04), a nonsignificant interaction effect was observed for stroke/SE by
dose (p = 0.84) [12]. In contrast, the subanalysis by Li et al. found no significant interaction
between initial apixaban dose and the treatment effects of apixaban versus warfarin on stroke/
SE (p = 0.848) and major bleeding (p = 0.561) [16]. However, comparative effectiveness and
safety outcomes for each apixaban dose regimen versus warfarin (in the respective US popula-
tions for which the dosages are indicated) have not been available. Therefore, the current
study evaluated patient outcomes in the 2 distinct populations for which apixaban was pre-
scribed in US clinical practice, reflecting real-world treatment patterns. In this study, we
pooled data from 4 US claims databases to compare baseline characteristics between patients
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who were prescribed 5 mg BID and 2.5 mg BID apixaban. The risk of stroke/SE and major
bleeding associated with 5 and 2.5 mg BID apixaban was also examined and compared to
warfarin.
Methods
A retrospective observational cohort study from January 1, 2012 to September 30, 2015 was
conducted using fully anonymized, pooled data from 4 large, nationally representative data-
bases in the US: the Truven MarketScan1 Commercial Claims and Encounter and Medicare
Supplemental and Coordination of Benefits Database (“MarketScan”), the IMS PharMetrics
Plus™ Database (“PharMetrics”), the Optum Clinformatics™ Data Mart (“Optum”), and the
Humana Research Database (“Humana”).
The pooled data included patient demographics, enrollment history, and medical and phar-
macy claims for more than 163 million members of commercial and Medicare Advantage/sup-
plemental plans. Medical claims from inpatient and outpatient healthcare settings were coded
using International Classification of Disease, 9th Revision, Clinical Modification (ICD-9-CM),
Current Procedural Terminology, or Healthcare Common Procedure Coding System codes,
and pharmacy claims data used the National Drug Code coding system to capture dispensed
drugs. Laboratory test results (eg, creatinine clearance) and biomarkers (eg, body weight) are
not comprehensively recorded in the 4 claims databases. Further explanation of the data
source can be found in a recent publication by Li et al. [16] that details results of a pooled anal-
ysis (using data from the same 4 databases outlined above) on the effectiveness and safety of
apixaban and warfarin [16]. To date, these databases used in the present study have also been
used in previous pooled analyses of various therapeutic areas [16–23].
In each database, patients were identified who met the following criteria: adults (aged18
years) with nonvalvular atrial fibrillation who had a pharmacy claim for apixaban or warfarin
during the identification period (January 1, 2013 to September 30, 2015). The first apixaban or
warfarin prescription claim date was defined as the index date. Patients were required to have
an atrial fibrillation diagnosis (ICD-9-CM code 427.31) before or on the index date and12
months of continuous medical and pharmacy health plan enrollment prior to the index date
(baseline period) [24].
Patients were excluded if they had evidence of pregnancy during the study period or valvular
heart disease, venous thromboembolism, transient atrial fibrillation (pericarditis, hyperthyroid-
ism, thyrotoxicity), or heart valve replacement/transplant during the 12 months prior to or on
the index date. Although the identification period was until September 30, 2015 (a day before
the Centers for Medicare & Medicaid Services required implementation of ICD-10 codes [Octo-
ber 1, 2015]), some health plans may have transitioned from ICD-9 to ICD-10 codes earlier.
Therefore, patients with any claims using ICD-10 codes during the study period were excluded.
Also excluded were patients prescribed any oral anticoagulant within 12 months before the
index date or>1 oral anticoagulant on the index date. The index apixaban dose was identified,
and patients were categorized as 5 mg BID or 2.5 mg BID apixaban patients.
The primary effectiveness outcome was stroke/SE, and the primary safety outcome was
major bleeding; these were identified using the first listed ICD-9-CM diagnosis code of inpa-
tient claims. Stroke/SE events included ischemic stroke, hemorrhagic stroke, and systemic
embolism; major bleeding included gastrointestinal bleeding, intracranial hemorrhage, and
other major bleeding. The diagnosis codes used for stroke/SE and major bleeding were based
on a validated algorithm developed for administrative claims data as well as the criteria for
major bleeding as defined by the International Society on Thrombosis and Haemostasis,
which were also used in the ARISTOTLE trial (S1 Table) [25, 26]. The follow-up period began
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the day after the index date and continued until censored at the first occurrence of any of the
following outcome events: 30 days after the discontinuation date (discontinuation being
defined as no evidence of index prescription for 30 days from the last day of supply of the last
filled prescription), the switch date to an oral anticoagulant other than that prescribed at
index, inpatient death, end of continuous medical and pharmacy enrollment, 1-year after the
index date, or the end of the study period (September 30, 2015). Patients were censored 1 year
after the index date to balance the follow-up time between the apixaban and warfarin cohorts.
Patient demographics and clinical characteristics during the 12 months prior to and on the
index date were measured. Comorbidities and clinical risk scores were assessed using ICD-
9-CM codes (eg, renal disease was defined with ICD-9-CM codes for nephritis, nephrotic syn-
drome, and nephrosis). Stroke and major bleeding risk were assessed using the respective
scores of CHA2DS2-VASc (congestive heart failure, hypertension, aged>75 years, diabetes,
prior stroke or transient ischemic attack or thromboembolism plus vascular disease, aged 65–
74 years, and sex) and HAS-BLED (hypertension, abnormal renal and liver function, stroke,
bleeding, labile international normalized ratios, age>65 years, drugs or alcohol abuse or
dependence) [27, 28]. International normalized ratios values were not available in the data-
bases and, therefore, not included in the HAS-BLED score calculation.
To examine differences in outcomes associated with the 2 dosing populations, propensity-
score matching (PSM) was conducted between 5 mg BID apixaban and warfarin patients and 2.5
mg BID apixaban and warfarin patients within each database to minimize selection bias and
adjust for potential confounders. We performed logistic regressions using the baseline variables of
age, sex, US geographic region, Charlson comorbidity index score, baseline bleeding and stroke/
SE history, comorbidities, and baseline comedications to obtain the propensity score for the prob-
ability of using apixaban. The PSM cohorts were created using the nearest-neighbor-matching
algorithm without replacement, with a caliper of 0.01 [29]. The balance of covariates was checked
based on standardized differences with a threshold of 10% [30]. After ensuring cohorts were bal-
anced within each of the databases following 1:1 PSM, the resulting patient records were pooled.
A head-to-head comparison between 5 mg BID and 2.5 mg BID apixaban was conducted to
compare baseline differences between the 2 cohorts. P-values were calculated from chi-square
and t-tests for categorical and continuous variables, respectively.
Incidence rates were calculated as the number of events divided by the time at risk and pre-
sented per 100 person-years. The cumulative incidence of major bleeding and stroke was eval-
uated using Kaplan-Meier survival curves. The risk of stroke/SE and major bleeding between
the matched cohorts (5 mg BID apixaban vs warfarin; 2.5 mg BID apixaban vs warfarin) was
evaluated using Cox proportional hazards models with robust sandwich estimates [29]. Apixa-
ban (2.5 mg BID or 5 mg BID) or warfarin treatment was included as the independent variable.
For the 5 mg BID apixaban analysis, no other covariates were included in the model because
the matched cohorts were balanced; however, for the 2.5 mg BID apixaban analysis, age had an
imbalance after matching and was, therefore, adjusted in the models. The log-log of the
Kaplan-Meier survival curves was visually inspected to check the proportional hazards
assumption. A p value<0.05 was considered statistically significant.
A sensitivity analysis was conducted among 2.5 mg BID and 5 mg BID apixaban-matched
warfarin patients for the entire follow-up period (not restricted to 1 year).
Results
Across all data sources, 115,186 nonvalvular atrial fibrillation patients were identified between
January 1, 2013 and September 30, 2015, including 41,867 (36.3%) apixaban and 73,319
(63.7%) warfarin patients (Fig 1).
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Because 15 apixaban patients had claims for both doses of apixaban on the index date, they
were not included in the analysis. Of the 41,852 patients with a single dose of apixaban on the
index date, 35,105 (83.9%) were prescribed 5 mg BID and 6747 (16.1%) patients were pre-
scribed 2.5 mg BID. Compared with warfarin patients, 5 mg BID apixaban patients were signif-
icantly younger (67.7 years vs 72.6 years, p< 0.001) and had lower stroke and major bleeding
risk scores (CHA2DS2-VASc: 2.9 vs 3.6 and HAS-BLED: 2.4 vs 2.8, p< 0.001). However, 2.5
mg BID apixaban patients were older (82.5 years vs 72.6 years, p< 0.001) and had higher
stroke and major bleeding risk scores (CHA2DS2-VASc: 4.5 vs 3.6 and HAS-BLED: 3.4 vs 2.8,
p< 0.001) compared with warfarin patients (S2 Table).
After 1:1 PSM, 31,827 5 mg BID apixaban patients were matched to 31,827 warfarin
patients, and 6600 2.5 mg BID apixaban patients were matched to 6600 warfarin patients. Base-
line characteristics of the matched populations are listed in Table 1.
Fig 1. Patient selection flowchart. 15 Patients had both doses of apixaban on the index date, so they were not included in
the analysis. AF: atrial fibrillation; BID: twice daily; ICD-10-CM: International Classification of Disease, 10th Revision,
Clinical Modification; VTE: venous thromboembolism.
https://doi.org/10.1371/journal.pone.0191722.g001
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Table 1. Baseline characteristics for PSM-adjusted 5 mg BID apixaban and warfarin and 2.5 mg BID apixaban and warfarin patients.
Parameter 5 mg BID Apixaban
Cohort
2.5 mg BID Apixaban Cohort Warfarin Cohort Warfarin Cohort
(5 mg BID Matched) (2.5 mg BID Matched)
N/Mean %/SD N/Mean %/SD P-valuea N/Mean %/SD N/Mean %/SD
Sample Size 31,827 6,600 31,827 6,600
Age, years 68.6 11.0 82.5 9.5 <0.001 69.2 11.7 80.1 8.5
18–54 3058 9.6% 84 1.3% <0.001 3105 9.8% 82 1.2%
55–64 8560 26.9% 288 4.4% <0.001 8524 26.8% 275 4.2%
65–74 10,016 31.5% 602 9.1% <0.001 9879 31.0% 588 8.9%
75 10,193 32.0% 5626 85.2% <0.001 10,319 32.4% 5655 85.7%
Gender
Male 20,007 62.9% 2756 41.8% <0.001 20,048 63.0% 2760 41.8%
Female 11,820 37.1% 3844 58.2% <0.001 11,779 37.0% 3840 58.2%
United States Geographic Region
Northeast 4876 15.3% 977 14.8% 0.287 4816 15.1% 983 14.9%
Midwest 8657 27.2% 1608 24.4% <0.001 8614 27.1% 1628 24.7%
South 13,428 42.2% 2841 43.0% 0.201 13,405 42.1% 2813 42.6%
West 4586 14.4% 1154 17.5% <0.001 4730 14.9% 1144 17.3%
Other 280 0.9% 20 0.3% <0.001 262 0.8% 32 0.5%
Baseline Comorbidity
Deyo-Charlson Comorbidity Index Score 2.3 2.3 3.6 2.7 <0.001 2.3 2.3 3.5 2.7
CHADS2 score 1.9 1.2 2.9 1.2 <0.001 1.9 1.2 2.9 1.2
0 3491 11.0% 82 1.2% <0.001 3289 10.3% 61 0.9%
1 9522 29.9% 623 9.4% <0.001 9400 29.5% 604 9.2%
2 9991 31.4% 2151 32.6% 0.057 10,384 32.6% 2244 34.0%
3+ 8823 27.7% 3744 56.7% <0.001 8754 27.5% 3691 55.9%
CHA2DS2-VASc score 3.0 1.7 4.5 1.5 <0.001 3.0 1.7 4.5 1.5
0 2381 7.5% 45 0.7% <0.001 2226 7.0% 27 0.4%
1 3781 11.9% 87 1.3% <0.001 3886 12.2% 91 1.4%
2 6555 20.6% 305 4.6% <0.001 6458 20.3% 306 4.6%
3 7388 23.2% 1084 16.4% <0.001 7566 23.8% 1092 16.5%
4+ 11,722 36.8% 5079 77.0% <0.001 11,691 36.7% 5084 77.0%
3+ 19,110 60.0% 6163 93.4% <0.001 19,257 60.5% 6,176 93.6%
HAS-BLED scoreb 2.5 1.3 3.3 1.3 <0.001 2.4 1.3 3.3 1.3
0 1858 5.8% 28 0.4% <0.001 1853 5.8% 23 0.3%
1 5734 18.0% 344 5.2% <0.001 5754 18.1% 357 5.4%
2 9487 29.8% 1422 21.5% <0.001 9638 30.3% 1461 22.1%
3+ 14,748 46.3% 4806 72.8% <0.001 14,582 45.8% 4759 72.1%
Bleeding history 4922 15.5% 1457 22.1% <0.001 4780 15.0% 1440 21.8%
Congestive heart failure 6835 21.5% 2450 37.1% <0.001 6804 21.4% 2426 36.8%
Diabetes mellitus 10,234 32.2% 2235 33.9% 0.007 10,357 32.5% 2274 34.5%
Hypertension 25,907 81.4% 5862 88.8% <0.001 25,959 81.6% 5880 89.1%
Renal disease 5044 15.8% 2535 38.4% <0.001 5091 16.0% 2546 38.6%
Liver disease 1437 4.5% 281 4.3% 0.357 1347 4.2% 260 3.9%
Myocardial infarction 2630 8.3% 787 11.9% <0.001 2532 8.0% 777 11.8%
Dyspepsia or stomach discomfort 5219 16.4% 1442 21.8% <0.001 5089 16.0% 1428 21.6%
Non-stroke/SE peripheral vascular Disease 13,686 43.0% 3738 56.6% <0.001 13,521 42.5% 3788 57.4%
Stroke/SE 2835 8.9% 1051 15.9% <0.001 2775 8.7% 1041 15.8%
Transient ischemic attack 1779 5.6% 628 9.5% <0.001 1736 5.5% 593 9.0%
(Continued)
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In both the 5 mg BID apixaban and matched warfarin populations, patients had an average
age of 69 years, with 37% female. Both cohorts had similar clinical characteristics: mean Charl-
son comorbidity index, CHA2DS2-VASc, and HAS-BLED scores were 2.3, 3.0, and 2.5, respec-
tively. During the baseline period, approximately 9% and 15% of patients had a prior stroke/
SE and bleed event, respectively. Similarly, 16% of patients had renal disease during the base-
line period.
In general, the characteristics of 2.5 mg BID apixaban and matched warfarin patients were
well balanced. Age was the only variable that had a standardized difference >10% between the
cohorts (2.5 mg BID apixaban: 82.5 years; warfarin: 80.1 years; standardized difference = 26%);
all the other characteristics were well balanced (Table 1).
The characteristics of patients prescribed 2.5 mg BID apixaban varied substantially from
those prescribed 5 mg BID apixaban. Patients prescribed 2.5 mg BID apixaban were signifi-
cantly older (average age: 82.5 vs 68.6 years, p< 0.001) and more likely to be women (58.2% vs
37.1%, p< 0.001) than those who were prescribed 5 mg BID apixaban. Patients prescribed 2.5
mg BID apixaban had a significantly greater proportion of patients older than 80 years (74.3%
vs 16.1%, p< 0.001) compared with those prescribed 5 mg BID apixaban. In addition, more
patients aged<75 years (68.0% vs 14.8%, p< 0.001) and<65 years (36.5% vs 5.6%, p< 0.001)
were prescribed 5 mg BID than 2.5 mg BID apixaban. Patients prescribed 2.5 mg BID apixaban
had a significantly higher proportion of prior stroke/SE during the baseline period compared
with those prescribed 5 mg BID apixaban (15.9% vs 8.9%, p< 0.001). In addition, 2.5 mg BID
apixaban patients had a significantly higher proportion of prior bleeding compared to 5 mg
Table 1. (Continued)
Parameter 5 mg BID Apixaban
Cohort
2.5 mg BID Apixaban Cohort Warfarin Cohort Warfarin Cohort
(5 mg BID Matched) (2.5 mg BID Matched)
N/Mean %/SD N/Mean %/SD P-valuea N/Mean %/SD N/Mean %/SD
Anemia and coagulation defects 5166 16.2% 1968 29.8% <0.001 5034 15.8% 1995 30.2%
Alcoholism 727 2.3% 72 1.1% <0.001 718 2.3% 56 0.8%
Baseline Medication Use
ACE/ARB 18,558 58.3% 4003 60.7% <0.001 18,749 58.9% 4047 61.3%
Amiodarone 3277 10.3% 961 14.6% <0.001 3165 9.9% 947 14.3%
Beta-blockers 19,050 59.9% 4057 61.5% 0.015 19,000 59.7% 4041 61.2%
H2-receptor antagonist 1536 4.8% 454 6.9% <0.001 1511 4.7% 441 6.7%
Proton pump inhibitor 8421 26.5% 2189 33.2% <0.001 8308 26.1% 2098 31.8%
Statins 17,884 56.2% 3961 60.0% <0.001 18,027 56.6% 3973 60.2%
Antiplatelets 4774 15.0% 1424 21.6% <0.001 4695 14.8% 1431 21.7%
NSAIDs 7661 24.1% 1401 21.2% <0.001 7610 23.9% 1355 20.5%
Follow-up time (mean, days) 179.4 163.2 179.1 163.1 199.5 194.8 204.4 192.6
Median 119 119 121 129
Follow-up time (mean, days) within 1 year 158.3 114.6 158.2 115.1 164.9 117.5 170.4 117.8
Median 119 119 121 129
ACE: angiotensin-converting enzyme inhibitor; ARB: angiotensin-receptor blocker; CHADS2: congestive heart failure, hypertension, age75 years, diabetes mellitus,
prior stroke or transient ischemic attack or thromboembolism; CHA2DS2-VASC: congestive heart failure, hypertension, age 75 years, diabetes mellitus, prior stroke or
transient ischemic attack or thromboembolism, vascular disease, age 65–74 years, sex category; HAS-BLED: hypertension, abnormal renal and liver function, stroke,
bleeding, labile international normalized ratios, elderly, drugs and alcohol; NSAIDs: nonsteroidal anti-inflammatory drugs; PSM: propensity-score–matched; SD:
standard deviation; stroke/SE: stroke/systemic embolism.
aNote: P-values indicate statistical test comparison between 5 mg BID and 2.5 mg BID apixaban patients.
bAs the international normalized ratio value is not available in the databases, a modified HAS-BLED score was calculated with a range of 0 to 8.
https://doi.org/10.1371/journal.pone.0191722.t001
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BID patients (22.0% vs 15.5%, p< 0.001). Also, the prevalence of renal disease was signifi-
cantly higher among 2.5 mg BID apixaban patients compared with 5 mg BID patients (38.4%
vs 15.8%, p< 0.001).
Comorbidity, stroke, and bleeding risk scores for the 2.5 mg BID apixaban patients (ie,
mean Charlson comorbidity index, CHA2DS2-VASc, and HAS-BLED scores) were 3.6, 4.5,
and 3.3, respectively; all scores were significantly higher than those for the 5 mg BID apixaban
patients (2.3, 3.0, and 2.5, respectively; all p< 0.001). Specifically, a significantly greater pro-
portion of 2.5 mg BID apixaban patients had a CHA2DS2-VASc score3 (93.4% vs 60.0%,
p< 0.001), CHA2DS2-VASc score4 (77.0% vs 36.8%, p< 0.001), and HAS-BLED score3
(72.8% vs 46.3%, p< 0.001) compared with 5 mg BID apixaban patients.
By restricting the follow-up period to 1 year, the difference in follow-up duration between
patients prescribed apixaban and warfarin was reduced. The average follow-up time was
approximately 5–6 months in the matched populations. Although most patients (85%) had a
follow-up shorter than 1 year, the maximum follow-up was 2.7 years.
When compared with matched warfarin patients, 5 mg BID apixaban patients had a lower
incidence of stroke/SE (2.2 vs 3.0 per 100 person-years; Table 2).
The cumulative incidence of stroke/SE is shown in Fig 2A.
The 5 mg BID apixaban was associated with a 30% lower risk of stroke/SE (hazard ratio
[HR]: 0.70, 95% confidence interval [CI]: 0.60–0.81) within 1 year of treatment initiation com-
pared with warfarin. Patients prescribed 5 mg BID apixaban also had a 30% reduction in ische-
mic stroke (HR: 0.70, 95% CI: 0.60–0.82) and a 61% reduction in SE (HR: 0.39, 95% CI: 0.20–
0.78). Apixaban patients had a nonsignificant trend toward a lower risk of hemorrhagic stroke
(HR: 0.77, 95% CI: 0.53–1.13) compared with warfarin patients (Fig 2B).
The incidence of stroke/SE was 3.5 and 5.3 per 100 person-years among the 2.5 mg BID
apixaban and matched warfarin patients, respectively (Table 3).
The cumulative incidence of stroke/SE is shown in Fig 3A.
Compared with warfarin, 2.5 mg BID apixaban was associated with a 37% lower risk of
stroke/SE (HR: 0.63, 95% CI: 0.49–0.81), driven by a 39% reduction in ischemic stroke (HR:
0.61, 95% CI: 0.46–0.80). Apixaban patients had a nonsignificant trend toward a lower risk of
hemorrhagic stroke (HR: 0.62, 95% CI: 0.32–1.20) and SE (HR: 0.61, 95% CI: 0.23–1.62) com-
pared with warfarin (Fig 3B).
Table 2. Number of events and incidence rates of clinical outcomes within 1 year for 5 mg BID apixaban and warfarin patients.
Warfarin Cohort 5 mg BID
Apixaban Cohort
n = 31,827 n = 31,827
Patients With Event Incidence Ratea Patients With Event Incidence Ratea
Stroke/SE 440 3.04 299 2.15
Ischemic stroke 368 2.54 251 1.80
Hemorrhagic stroke 63 0.43 47 0.34
SE 29 0.20 11 0.08
Major bleeding 977 6.80 563 4.05
Intracranial hemorrhage 142 0.98 86 0.61
Gastrointestinal bleeding 476 3.29 288 2.07
Other major bleeding 436 3.01 232 1.66
aEvent rates are shown per 100 person-years.
BID: twice daily; SE: systemic embolism.
https://doi.org/10.1371/journal.pone.0191722.t002
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Fig 2. Cumulative incidence and hazard ratios of stroke/systemic embolism among 5 mg BID apixaban/warfarin
patients. (A) Cumulative incidence of stroke/SE among propensity-score–matched 5 mg BID apixaban and warfarin
patients. (B) Hazard ratios of stroke/SE for propensity-score–matched 5 mg BID apixaban and warfarin patients. BID,
twice daily; stroke/SE, stroke/systemic embolism.
https://doi.org/10.1371/journal.pone.0191722.g002






Patients With Event Incidence Ratea Patients With Event Incidence Ratea
Stroke/SE 163 5.28 101 3.51
Ischemic stroke 136 4.40 82 2.84
Hemorrhagic stroke 23 0.74 13 0.45
SE 11 0.35 6 0.21
Major bleeding 326 10.64 188 6.56
Intracranial hemorrhage 54 1.73 29 1.00
Gastrointestinal bleeding 159 5.14 89 3.09
Other bleeding 136 4.39 86 2.98
aEvent rates are shown per 100 person-years.
BID: twice daily; SE: systemic embolism.
https://doi.org/10.1371/journal.pone.0191722.t003
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The incidence rate of major bleeding was lower among 5 mg BID apixaban patients com-
pared with matched warfarin patients (4.1 vs 6.8 per 100 person-years). The cumulative inci-
dence of major bleeding is shown in Fig 4A.
Patients prescribed 5 mg BID apixaban had a 41% lower risk of major bleeding (HR: 0.59,
95% CI: 0.53–0.66) within 1 year of treatment initiation compared with those prescribed war-
farin. This reduced major bleeding risk was driven by a reduced risk of gastrointestinal bleed-
ing (HR: 0.62, 95% CI: 0.54–0.72), intracranial hemorrhage (HR: 0.63, 95% CI: 0.48–0.82), and
other major bleeding (HR: 0.55, 95% CI: 0.47–0.64) (Fig 4B).
The incidence of major bleeding was 6.6 and 10.6 per 100 person-years for 2.5 mg BID apix-
aban and matched warfarin patients, respectively (Table 3). The cumulative incidence of
major bleeding is shown in Fig 5A.
Patients prescribed 2.5 mg BID apixaban were associated with a 41% lower risk of major
bleeding (HR: 0.59, 95% CI: 0.49–0.71) within 1 year of treatment initiation, a 43% reduction
in gastrointestinal bleeding (HR: 0.57, 95% CI: 0.44–0.75), 44% reduction in intracranial hem-
orrhage (HR: 0.56, 95% CI: 0.36–0.88), and 35% reduction in other major bleeding (HR: 0.65,
95% CI: 0.49–0.86) compared with those prescribed warfarin (Fig 5B).
Fig 3. Cumulative incidence and hazard ratios of stroke/systemic embolism among 2.5 mg BID apixaban/warfarin
patients. (A) Cumulative incidence of stroke/SE among propensity-score–matched 2.5 mg BID apixaban and warfarin
patients. (B) Hazard ratios of stroke/SE for propensity-score–matched 2.5 mg BID apixaban and warfarin patients.
Footnote: BID: twice daily; stroke/SE, stroke/systemic embolism.
https://doi.org/10.1371/journal.pone.0191722.g003
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In a sensitivity analysis, the risk of major bleeding and stroke over the entire follow-up
period was examined for both matched populations. Patients prescribed 5 mg BID apixaban
had a significantly lower risk of stroke (HR: 0.70, 95% CI: 0.60–0.80) and major bleeding (HR:
0.59, 95% CI: 0.54–0.65) compared with warfarin. Patients prescribed 2.5 mg BID apixaban
also had a significantly lower risk of stroke (HR: 0.64, 95% CI: 0.50–0.82) and major bleeding
(HR: 0.63, 95% CI: 0.53–0.74) compared with those prescribed warfarin.
Discussion
In this real-world retrospective observational analysis, our principal findings are as follows: (I)
patients prescribed 5 mg apixaban BID had different characteristics from those prescribed 2.5
mg BID apixaban, and (II) 5 mg BID and 2.5 mg BID apixaban were associated with signifi-
cantly lower risk of stroke/SE and major bleeding compared with warfarin when assessed as 2
distinct patient populations. To our knowledge, this is the first dose-specific analysis compar-
ing 5 mg BID and 2.5 mg BID apixaban with warfarin using US claims data.
Fig 4. Cumulative incidence and hazard ratios of major bleeding among 5 mg BID apixaban and warfarin
patients. (A) Cumulative incidence of major bleeding among propensity-score–matched 5 mg BID apixaban and
warfarin patients. (B) Hazard ratio of major bleeding for propensity-score–matched 5 mg BID apixaban and warfarin
patients. BID, twice daily.
https://doi.org/10.1371/journal.pone.0191722.g004
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In the current study, baseline characteristics were compared between patients who took 5
mg BID apixaban and those who took 2.5 mg BID apixaban. Apixaban dosages were associated
with markedly different patient characteristics. Patients prescribed apixaban 2.5 mg BID were
substantially older, mostly women, had clinically more severe comorbidities, and were more
likely to have a history of stroke and bleeding compared with those prescribed 5 mg BID apixa-
ban. In addition, 2.5 mg BID apixaban patients were more than twice as likely to have renal
disease compared with 5 mg BID apixaban patients. In this real-world study, 5 mg BID and 2.5
mg BID apixaban were observed to be used in the patient subgroups that differed widely in age
and clinical characteristics. Although it cannot be ascertained from claims data whether dose
selection matched the label-indicated criteria for 2.5 mg BID use, higher mean age and more
prevalent renal disease in the 2.5 mg BID apixaban group were consistent with the criteria.
In the current study, 5 mg BID and 2.5 mg BID apixaban patients were associated with
lower risks of stroke/SE and major bleeding compared with matched warfarin patients. These
reductions were consistent for 5 mg BID and 2.5 mg BID apixaban compared with warfarin.
Patients prescribed 5 mg BID apixaban had a 30% reduction in risk of stroke/SE compared
with warfarin, and those prescribed 2.5 mg BID apixaban had a 37% reduction in risk for
Fig 5. Cumulative incidence and hazard ratios of major bleeding among 2.5 mg BID apixaban and warfarin
patients. (A) Cumulative incidence of major bleeding among propensity-score–matched 2.5 mg BID apixaban and
warfarin patients. (B) Hazard ratio of major bleeding for propensity-score–matched 2.5 mg BID apixaban and
warfarin patients. BID: twice daily; GI: gastrointestinal bleeding; ICH: intracranial hemorrhage.
https://doi.org/10.1371/journal.pone.0191722.g005
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stroke/SE. In addition, the safety analysis showed that 5 mg BID apixaban versus warfarin, and
2.5 mg BID apixaban versus warfarin, had the same magnitude of risk reduction (41%) for
major bleeding. In the sensitivity analysis, the results were consistent when the entire follow-
up period was used.
In the ARISTOTLE trial, apixaban use showed a 21% lower risk of stroke/SE and a 31%
lower risk of major bleeding compared with warfarin use [5]. Although the ARISTOTLE trial
did not evaluate stroke and major bleeding in 5 mg BID and 2.5 mg BID apixaban doses sepa-
rately due to the small sample size of the latter group, previous ARISTOTLE trial subgroup
analysis did not find a significant interaction between dose and treatment effect when evaluat-
ing stroke/SE and major bleeding [5].
In previously published US real-world studies, most apixaban dose-related analyses were
treatment-by-dose interaction or sensitivity analysis with a 5 mg BID apixaban regimen
restriction. In a recent publication using OptumLabs data, apixaban patients (n = 7695) were
shown to have a significantly lower risk of stroke/SE and major bleeding compared with warfa-
rin patients [12]. Subgroup analyses based on apixaban dose regimens indicated no significant
treatment-by-dose interaction for stroke/SE (p = 0.84), but significant interaction for major
bleeding (p = 0.04) [12]. In the OptumLabs study, 5 mg BID apixaban was associated with a
62% lower risk of major bleeding (HR: 0.38, 95% CI: 0.28–0.53) compared with warfarin. The
HR for major bleeding risk between 2.5 mg BID apixaban and warfarin was<1, but not statis-
tically significant (HR: 0.74, 95% CI: 0.44–1.25), which may have been due to the small sample
size of the 2.5 mg BID apixaban group (n < 1400) [12]. Another recent publication based on a
pooled analysis of 4 US claims databases also found lower risk of stroke/SE and major bleeding
in apixaban patients (n = 38,470, including 6568 on 2.5 mg BID) compared with warfarin
patients. However, the subgroup interaction analysis on dose regimen did not result in statisti-
cally significant differences in the respective treatment effect between the 2 dose regimens
[16]. In a sensitivity analysis of a recent comparative safety study using MarketScan data, 5 mg
BID apixaban patients (n = 5961) had a 45% lower risk of major bleeding compared with war-
farin patients (HR: 0.55; 95% CI: 0.39–0.77) [9].
Another recently published study using OptumLabs data [13] directly compared outcomes
between patients treated with 5 mg BID apixaban and those treated with 2.5 mg BID apixaban,
without including warfarin patients as a comparator group. Although data on patient body
weight were not available and laboratory values on renal function were available only for
approximately one-third of patients in this analysis, the findings suggest that NOAC dosing in
real-world practice may be inconsistent with recommendations in drug labeling. In addition,
dosing that is inconsistent with recommendations in labeling may impact outcomes. Among
apixaban patients without a serum creatinine level 1.5 mg/dL (ie, without a renal indication
for dose reduction), authors reported elevated risk of stroke/SE for those on 2.5 mg BID apixa-
ban (n = 550) compared with those on 5 mg BID apixaban (n = 550; the 2 groups were
matched with propensity score). This finding suggests the importance of appropriate dosing of
apixaban according to its label. A limitation of the analysis was the relatively small sample size
and corresponding low number of events (eg, the comparison described above was based on
only 7 stroke/SE events).
The use of 2.5 mg BID apixaban is more prevalent in European countries (30% to 40%)
compared with the United States (10% to 20%) [9, 11, 12, 15, 31–35]. Using the Danish
National Patient Register databases, 2 recently published studies separately compared the
effectiveness and safety of 5 mg BID apixaban (n = 6349) and 2.5 mg BID apixaban (n = 4400)
with warfarin in Danish clinical practice [11, 15]. Inverse probability of treatment-weighted
methods were used to control for differences in patient characteristics, but residual confound-
ing may still exist as mentioned by the authors. An intent-to-treat approach was applied for all
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endpoints in both studies without censoring the follow-up time when a patient discontinued
index therapy or switched to a different therapy. The study comparing 2.5 mg BID apixaban
with warfarin showed that patients prescribed 2.5 mg BID apixaban were older and had higher
stroke and bleeding risk as measured by CHA2DS2-VASc and HAS-BLED scores [11]. In a
study comparing 5 mg BID apixaban with warfarin, 5 mg BID apixaban was found to be asso-
ciated with a lower risk of major bleeding but no significant difference in the risk of ischemic
stroke/SE [15]. The analysis comparing 2.5 mg BID apixaban with warfarin did not find signif-
icant differences in the risk of ischemic stroke/SE and major bleeding between the 2 cohorts
[11].
These findings from the Danish registries are somewhat different from our current study.
The different findings may be related to the variance in patient population and prescription
pattern (eg, the ratio of 5 mg BID and 2.5 mg BID apixaban patients was approximately 1.5:1
in Danish studies but approximately 5:1 in the current study), sample size (10,749 apixaban
patients in Danish studies and 38,427 apixaban patients in the current study), endpoint selec-
tion (eg, ischemic stroke/SE vs stroke/SE as the primary effectiveness measure), and statistical
methods (eg, inverse probability of treatment-weighted method vs PSM method, and whether
censoring follow-up when discontinuation or switch occurred) [11, 15].
The similar effectiveness and safety outcomes being observed for the 5 mg BID and 2.5 mg
BID of apixaban in this study do not indicate that the dose regimens should be considered
therapeutically equivalent or interchangeable. Use of 2.5 mg BID apixaban should follow ther-
apeutic labels. The unique patient characteristics associated with the 2.5 mg BID selection
(older age and higher prevalence of renal disease) are likely important factors that helped
achieve the lower risk of stroke/SE and major bleeding for 2.5 mg BID apixaban patients com-
pared with warfarin in this study. These factors are generally consistent with prescribing infor-
mation recommendations.
A key strength of this study is the size of the sample of patients we were able to obtain by
pooling matched populations from 4 large, nationally representative US claims databases. By
combining data sources, we were able to obtain a much larger sample size of apixaban patients
than previously published studies, increasing the statistical power and allowing us to evaluate
effectiveness and safety outcomes not only among patients with commonly used 5 mg BID
apixaban but also among less prevalent 2.5 mg BID apixaban patients. The pooling of 4 data
sources also improves the generalizability of our study findings. Furthermore, our study is the
first analysis in which PSM was completed separately between each apixaban dose and
warfarin.
Our study has several limitations. First, due to the retrospective observational design,
results are estimates of statistical association, and no causal relationships should be inferred.
PSM was applied to the cohorts to reduce confounding; however, residual confounding from
unmeasured variables, such as over-the-counter use of aspirin or changes in warfarin dose,
may remain. Laboratory data such as creatinine clearance levels or international normalized
ratios were not comprehensively captured in the administrative claims data. We were not able
to ascertain whether the dose selection matches the indicated criteria because information
regarding body weight and serum creatinine was not available; however, the increased age and
higher percentage of renal disease in the 2.5 mg BID apixaban group are consistent with the
indicated criteria. Also, misclassification errors may have occurred because some ICD-9-CM
codes may have been incorrectly recorded, misused, or never entered. This study included
only treatment-naïve apixaban and warfarin patients to avoid potential confounding associ-
ated with therapy switch. Patients who switched from warfarin to apixaban may have done so
due to poor quality of international normalized ratio control, which cannot be measured in
the data source, or may be different from patients who continued using warfarin in other ways
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that could introduce bias. Although the sample size used for this observational study is consid-
erably larger than that of the 2.5 mg dosing group included in the ARISTOTLE trial (6,600
patients vs 428 patients, respectively), study results should be considered for hypothesis gener-
ation only and not be considered as conclusive [5].
Several limitations related to the data source were present in this analysis. Although over-
lapping at the health plan level is expected to be minimal across different health plans contrib-
uting data to any of the 4 databases, duplicate patient records may exist across the databases,
especially between the 2 employer-based claims databases (MarketScan and PharMetrics);
however, the percentage of those potential duplicates in a previously published pooled analysis
of the 2 databases was estimated to be small (0.5%) and, therefore, not likely to affect the results
[17]. There is also the potential for observed and unobserved heterogeneity among the 4 data-
bases due to differences in health plans and patient populations covered in each database. To
address this, PSM was conducted within each database prior to pooling the matched patient
records across databases. In an exploratory analysis, the interaction terms between treatment
effect and each database were not significant and the results were consistent across the 4 data-
bases. Lastly, the data source did not comprehensively contain renal function laboratory values
or body weight, and therefore it could not be fully ascertained whether patients met age, body
weight, and creatinine level criteria for dose reduction, as defined in the ARISTOTLE trial and
the prescribing information for apixaban [5]. Although some US data sources (particularly
those linking or integrating data from both insurance claims and electronic medical records)
may have comprehensive body weight and renal function laboratory values available, feasibility
assessment and previous literature suggested that the sample size of 2.5 mg BID apixaban
patients in those data sources would be quite small. For example, only 550 2.5 BID apixaban
patients were included in a recently published propensity-score matched analysis using
OptumLabs data [13]. The current study was conducted in an attempt to better understand
characteristics and outcomes associated with 2.5 mg BID apixaban patients based on a large
sample of those patients treated in US clinical practice.
Finally, this real-world study differs from clinical trials in several ways [36]. First, the identi-
fication of stroke/SE and major bleeding events was based on administrative claims and was
not verified with a review of medical records; in contrast, these events were adjudicated in the
ARISTOTLE trial [5]. Inclusion and exclusion criteria for the present real-world study were
less stringent than those required in the clinical trial, and the patient sample size was larger. In
addition, patients receiving warfarin in routine clinical practice may have had a reduced time
in therapeutic range (TTR) compared to those in a clinical trial—potentially due to less fre-
quent international normalized ratio (INR) monitoring and warfarin management—which
may have led to higher rates of ischemic stroke and gastrointestinal bleeding observed in the
present study versus those in the clinical trial setting [37]. Although INR values for patients
receiving treatment with warfarin were not available in the databases used in this study, prior
research using ARISTOTLE trial data has suggested that the treatment effects of apixaban
compared with warfarin on stroke/SE and major bleeding appear similar across the range of
predicted quality of INR control [38].
Conclusion
In this real-world study, 5 mg BID and 2.5 mg BID doses of apixaban were assessed for 2
patient groups that differed widely in age and clinical characteristics. Each apixaban dose was
associated with a lower risk of stroke/SE and major bleeding compared with warfarin in the
distinct population for which it is currently prescribed in US clinical practice. This study pro-
vides observational evidence to supplement the results of the ARISTOTLE trial, which found
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no significant interaction between dose and treatment effect regarding stroke/SE and major
bleeding [5]. To confirm the findings of this observational study, additional research should be
performed using different data sources (ideally data sources with comprehensive body weight
and renal function laboratory values) and larger patient sample sizes.
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